CSE: SONA | OTCQB: SNANF

+1-902-442-0653 Purdy’s Wharf Tower II Suite 2001 – 1969 Upper Water Street

Home
Science
Pipeline
Investors
News & Media
About

Category: Insights

News & Media — Insights

Insights

Subscribe to Our Newsletter

Download the Company Presentation

Read in Frontiers in Immunology our Published Research

Targeted intra-tumoral hyperthermia using uniquely biocompatible gold nanorods induces strong immunogenic cell death in two immunogenically ‘cold’ tumor models.

A clinical-stage oncology company advancing Targeted Hyperthermia Therapy for solid tumors, powered by uniquely biocompatible, CTAB-free gold nanorods.

Linkedin-in X-twitter Youtube

Science

Technology Overview
Targeted Hyperthermia Therapy
Scientific Evidence
Publications
Pipeline
Partnering

Investors

Share Information
Financial Reports
Investor Presentations
Research Coverage

News & Media

News Releases
Carman's Corner
Media Centre
Insights

About Us

Our Story
Leadership
Board of Directors
Advisory Board
Contact Us

Store

Order
Your Account
Shipping Information

© 2026 Sona Nanotech Inc. All rights reserved.

CSE: SONA · OTCQB: SNANF

Social Media Policy

Home
Science
Pipeline
Investors
News & Media
About